AML1-ETO is the chimeric protein product of t(8;21) in acute myeloid leukemia. The ETO portion of the fusion protein includes the nervy homology region (NHR) 3 domain, which shares homology with A-kinase anchoring proteins and interacts with the regulatory subunit of type II cAMP-dependent protein kinase A (PKA(RIIα)). We determined the solution structure of a complex between the AML1-ETO NHR3 domain and PKA(RIIα). Based on this structure, a key residue in AML1-ETO for PKA(RIIα) association was mutated. This mutation did not disrupt AML1-ETO's ability to enhance the clonogenic capacity of primary mouse bone marrow cells or its ability to repress proliferation or granulocyte differentiation. Introduction of the mutation into AML1-ETO had minimal impact on in vivo leukemogenesis. Therefore, the NHR3-PKA(RIIα) protein interaction does not appear to significantly contribute to AML1-ETO's ability to induce leukemia.
AML1-n class="Gene">ETO is the chimeric protein product of t(8;21) in acute myeloid leukemia. The ETO portion of the fusion protein includes the nervy homology region (NHR) 3 domain, which shares homology with A-kinase anchoring proteins and interacts with the regulatory subunit of type II cAMP-dependent protein kinase A (PKA(RIIα)). We determined the solution structure of a complex between the AML1-ETO NHR3 domain and PKA(RIIα). Based on this structure, a key residue in AML1-ETO for PKA(RIIα) association was mutated. This mutation did not disrupt AML1-ETO's ability to enhance the clonogenic capacity of primary mouse bone marrow cells or its ability to repress proliferation or granulocyte differentiation. Introduction of the mutation into AML1-ETO had minimal impact on in vivo leukemogenesis. Therefore, the NHR3-PKA(RIIα) protein interaction does not appear to significantly contribute to AML1-ETO's ability to induce leukemia.
Authors: Lora L Burns; Jaume M Canaves; Juniper K Pennypacker; Donald K Blumenthal; Susan S Taylor Journal: Biochemistry Date: 2003-05-20 Impact factor: 3.162
Authors: James C Mulloy; Jörg Cammenga; Karen L MacKenzie; Francisco J Berguido; Malcolm A S Moore; Stephen D Nimer Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: M H Tomasson; D W Sternberg; I R Williams; M Carroll; D Cain; J C Aster; R L Ilaria; R A Van Etten; D G Gilliland Journal: J Clin Invest Date: 2000-02 Impact factor: 14.808
Authors: Chi Wai So; Holger Karsunky; Emmanuelle Passegué; Antonio Cozzio; Irving L Weissman; Michael L Cleary Journal: Cancer Cell Date: 2003-02 Impact factor: 31.743
Authors: Zaw Min Oo; Anuradha Illendula; Jolanta Grembecka; Charles Schmidt; Yunpeng Zhou; Virginie Esain; Wanda Kwan; Isaura Frost; Trista E North; Roger A Rajewski; Nancy A Speck; John H Bushweller Journal: Leuk Lymphoma Date: 2017-12-18